Commentary

Radiation Sensitization of Leukemic Cells for Low Dose Total Body Irradiation

Einsley Janowski, Anatoly Dritschilo*

Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057, United States

ARTICLE INFO

Article history:
Received 10 March 2015
Received in revised form 12 March 2015
Accepted 12 March 2015
Available online 13 March 2015

Keywords:
Leukemia
Total body irradiation
TBI
Radiosensitization
TRAIL
Targeted therapy

The treatment of pediatric leukemias has been developed through sequential clinical trials designed to improve patient survival and preserve quality of life (Brochstein et al., 1987). A patient's clinical and biological features are predictive of risk of relapse and determine the aggressiveness of the prescribed clinical treatment protocol. Patients determined to be at high risk for recurrence undergo chemotherapy and total body irradiation (TBI) in the preparative regimen for bone marrow transplantation. Such personalization of treatment has resulted in improved survival. While the 5-year overall survival of pediatric leukemia patients ranges from 60–90% (Allemani et al., 2014), children who experience bone marrow relapse have a three year event free survival of only 20%, supporting the need for further improvements (Gaynon et al., 2006).

Leukemic cells are very sensitive to radiation induced apoptosis, but the magnitude of the TBI radiation dose is dictated not only by the need to control tumor cells, but also to respect normal tissue tolerances of critical organs. Dose dependent late-effects of TBI are of particular concern in the treatment of pediatric patients. In addition to acute pulmonary, cardiovascular, hepatic, and renal toxicities, treatment of children can result in endocrinopathies, neurocognitive impairment, growth disturbances, cataract formation and secondary malignancies as delayed effects (Silverman, 2014). Thus, pediatric clinical protocols focus on reducing or eliminating radiation; however, multiple clinical trials have shown that including TBI is more effective than chemotherapy alone, and even minor reductions of TBI dose have resulted in more relapses (Shi-Xia et al., 2010; Clift et al., 1998).

Although leukemias are generally considered radiation sensitive diseases, the clinically acceptable TBI doses are within tolerance of critical structures and may be insufficient for patient cure. Uckun's characterization of B-cells from recurrent leukemic patients as “radiation resistant” may be viewed in the context of such surviving malignant cells following exposure to conventional doses of TBI (Uckun et al., 2015). The high-risk B-precursor acute lymphoblastic leukemia (BPL) patients experience a high rate of relapse after conventional therapies and may benefit from innovative personalized treatment strategies based on an understanding of molecular genetics and pathogenesis of leukemias (Shi-Xia et al., 2010).

The development of a cancer specific radiosensitizer, to allow TBI dose reduction and to increase treatment effectiveness, is a highly desired goal for leukemia treatment. To this end, Uckun and colleagues report that CD19L-sTRAIL preferentially kills leukemic stem cells from B-cell precursor ALL patients and enhances the killing effects of low dose TBI (Uckun et al., 2015). Furthermore, survival benefit, safety and efficacy of the combination treatment are demonstrated in proof-of-concept experiments in a xenograft animal model. Thus, sensitization of B-precursor ALL by the combination of radiation and the CD19L-sTRAIL fusion protein has potential for improving efficacy of treatment and allowing reduction in the radiation dose used for TBI. Although the effectiveness of TRAIL targeted therapy has yet to be demonstrated in clinical trials, recombinant protein therapies show promise in solid tumor clinical applications for targeted cancer treatment. Uckun's proposal to include CD19L-sTRAIL in the pre-transplant TBI regimens for patients presenting with very high risk BPL is a rational and innovative translational goal.

Conflicts of Interest

The authors declared no conflicts of interest.

References

Allemani, C., Weir, H.K., Carreira, H., Harewood, R., Spika, D., Wang, X.S., Bannon, F., Ahn, J.W., Johnson, C.J., Bonaventure, A., Marcos-Gargera, R., Stiller, C., Azevedo E Silva, G., Chen, W.Q., Ogunbiyi, O.J., Rachet, B., Soeberg, M.J., You, H., Matsuda, T., Bielaska-Lasiota, M., Storm, H., Tucker, T.C., Coleman, M.P., the CONCORD Working Group, 2014. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet http://dx.doi.org/10.1016/S0140-6736(14)62038-9 (Nov 26. pii: S0140-6736(14)62038-9 [Epub ahead of print] PubMed PMID: 25467588).
Brochstein, J.A., Kernan, N.A., Groshen, S., Cirrincione, C., Shank, B., Emanuel, D., Laver, J., O’Reilly, R.J., 1987. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N. Engl. J. Med. 317 (26), 1618–1624 (Dec 24. PubMed PMID: 3317056).

Clift, R.A., Buckner, C.D., Appelbaum, F.R., Sullivan, K.M., Storb, R., Thomas, E.D., 1998. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 92 (4), 1455–1456 (Aug 15, PMID: 9694737).

Gaynon, P.S., Harris, R.E., Altman, A.J., Bostrom, B.C., Breneman, J.C., Hawks, R., Steele, D., Zipf, T., Strand, D.O., Villaluna, D., Trigg, M.E., 2006. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group study CCG-1941. J. Clin. Oncol. 24 (19), 3150–3156 (Jul 1, Epub 2006 May 22. PMID: 16717292).

Shi-Xia, X., Xian-Hua, T., Hai-Qin, X., Bo, F., Xiang-Feng, T., 2010. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk. Lymphoma 51 (1), 50–60. http://dx.doi.org/10.3109/10428190903419130 (Jan, PMID: 20055638).

Silverman, L.B., 2014. Balancing cure and long-term risks in acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2014 (1), 190–197. http://dx.doi.org/10.1182/asheducation-2014.1.190 (Dec 5, Epub 2014 Nov 18. PubMed PMID: 25696854).

Uckun, F.M., Myers, D.E., Ma, H., Rose, R., Qazi, S., 2015. Low dose total body irradiation combined with recombinant CD19-ligand × soluble TRAIL fusion protein is highly effective against radiation-resistant B-precursor acute lymphoblastic leukemia in mice. EBioMedicine 2 (4), 306–316.